---
title: "XtalPi × Vistra Tech: CureCMT Strategic Partnership Boosts RTX-117 and VoyageR AI Platform with Significant Catalysts"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40079986.md"
description: "I. Major Events • Xili Technology and the CureCMT Foundation have reached a strategic cooperation..."
datetime: "2026-04-21T21:07:26.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40079986.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40079986.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40079986.md)
author: "[周树人的交易员](https://longbridge.com/en/profiles/12816038.md)"
---

# XtalPi × Vistra Tech: CureCMT Strategic Partnership Boosts RTX-117 and VoyageR AI Platform with Significant Catalysts

I. Main Events  
• Xili Technology and the CureCMT Foundation have entered into a strategic partnership to jointly build the world's first AI-powered precision medicine platform for Charcot-Marie-Tooth disease (CMT) — the "iPSC + AI Virtual Cell" platform.  
• Core platform technology: Integration of isogenic induced pluripotent stem cell (Isogenic iPSC) disease models + AI Virtual Cell (AIVC) technology.  
• Main objectives:  
1) Improve patient stratification accuracy (enabling precise treatment matching);  
2) Accelerate the R&D progress of the core pipeline RTX-117;  
3) Lay the foundation for personalized/precision treatment in the CMT field.

II. Concise Summary  
• Using AI + real cell models, this transforms CMT treatment from a "one-size-fits-all" approach to a "tailor-made" one, directly helping the main pipeline RTX-117 progress faster and more accurately.  
• Simultaneously, it provides a strong boost to the VoyageR AI platform, further extending AI's role from "drug discovery" to the "precision medication" stage. In the short term, this can accelerate RTX-117's clinical progress; in the medium to long term, it enhances the commercialization potential of the entire RNA modulation pipeline.

III. Impact on the Joint Project with X-Tal, Based on the Latest CureCMT Strategic Partnership (iPSC + AI Virtual Cell Platform)  
• RTX-117: Direct, positive, and strongest impact. The new platform specifically targets CMT, significantly improving patient stratification accuracy, helping to better match patient subgroups suitable for RTX-117. It optimizes Phase I data interpretation, patient recruitment, and Ib/IIa phase design, reducing clinical failure risk. It further validates the incubation value, potentially triggering additional milestone payments and increasing long-term sales splits and licensing revenue.  
• VoyageR AI Platform: Strong positive impact. The new partnership extends VoyageR from the "drug discovery phase" to the precision medicine/virtual cell validation phase, achieving a "discovery-optimization-patient stratification" closed loop, enhancing the platform's overall conversion efficiency and credibility. Combined with X-Tal's AI + robotics platform, it strengthens data accumulation, enabling faster generation of new RNA modulation candidates in the future. It reinforces the synergistic image of "AI + RNA + robotics," facilitating more incubated pipeline outputs and platform licensing revenue.  
• Oncology RNA Modulators: Indirect/medium impact. There is potential for technological extension. The iPSC + AI virtual cell method could be analogously applied to tumor patient-derived models, improving target validation and "undruggable" target screening efficiency for oncology RNA modulators.

Thoughts on this deal: The biggest beneficiary of this collaboration is undoubtedly RTX-117, followed by the VoyageR AI platform. It is expected to bring more clinical catalysts and valuation uplift.

$XTALPI(02228.HK)

### Related Stocks

- [300024.CN](https://longbridge.com/en/quote/300024.CN.md)
- [02228.HK](https://longbridge.com/en/quote/02228.HK.md)
- [RTX.US](https://longbridge.com/en/quote/RTX.US.md)